Table 3.
Pooled sensitivity and specificity among subgroups of studies.
| Subgroups | No. of study | No. of tested individuals | Sensitivity | Specificity |
|---|---|---|---|---|
| (95 % CI) | (95 % CI) | |||
| Presence of symptoms | ||||
| Symptomatic | 13 studies | 9081 | 65.0 (63.0–67.0) | 98.0 (97.0–99.0) |
| Asymptomatic | 9 studies | 3696 | 64.0 (61.0−67.0) | 98.0 (97.0–99.0) |
| Antigen tests | ||||
| Lumipulse G | 4 studies | 6517 | 87.0 (85.0–90.0) | 97.0 (96.0–98.0) |
| COVID-19 Ag Respi-Strip | 4 studies | 736 | 39.0 (34.0–43.0) | 100 (98.0–100.0) |
| SD Biosensor | 12 studies | 6887 | 76.0 (73.0–78.0) | 99.0 (95.0–100) |
| Panbio | 15 studies | 12577 | 75.0 (73.0–76.0) | 100 (100–100) |
| BinaxNOW | 4 studies | 4725 | 57.0 (53.0–60.0) | 99.0 (99.0–100) |
| Roche Diagnostics | 7 studies | 5601 | 60.0 (58.0–63.0) | 98.0 (97.0–98.0) |
| Antigen detection technology | ||||
| Immunochromatography | 48 studies | 30128 | 72.0 (71.0–73.0) | 99.0 (99.0–99.0) |
| Chemiluminescent immunoassay | 6 studies | 9879 | 72.0 (69.0–74.0) | 98.0 (97.0–98.0) |
| Specimen types | ||||
| Nasopharyngeal Swab | 52 studies | 30251 | 70.0 (69.0–71.0) | 98.0 (98.0–98.0) |
| Other (Nasal and oral) | 3 studies | 3150 | 52.0 (48.0–57.0) | 100 (99.0–100) |
| Mean Ct values | ||||
| Ct value ≤ 25 | 15 studies | 7540 | 71.0 (70.0–73.0) | 98.0 (98.0–98.0) |
| Ct value >26 | 9 studies | 2988 | 67.0 (64.0–70.0) | 98.0 (98.0–99.0) |